Comparative Pharmacology
Head-to-head clinical analysis: HALOTEX versus KERYDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTEX versus KERYDIN.
HALOTEX vs KERYDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
None Documented
None Documented
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Category C
Category C
Antifungal
Antifungal